http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-534462-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132d1d8c55ea986beac122fcd6141457 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1206 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-527 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0491 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-527 |
| filingDate | 2003-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e90c36524503ee4e682fa31936f61b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f7c7d76882ba00f2f89ab02c76be2e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e55f174dcd778b87fb2e2db4b4d3b12e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ab3d10d435e3a3b8128eb041bf4ff1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3348c9e7d62338a5f277ed4a45ec9cc4 |
| publicationDate | 2007-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-534462-A |
| titleOfInvention | Test agents for evaluating pharmacological effect of drug, and method and reagents for screening drug having excellent administration effect and/or little side effect from among drugs comprising enzymes, enzyme inhibitors or receptor ligands and/or prodrugs thereof |
| abstract | It is intended to provide test agents for evaluating the pharmacological effect of a drug such as a drug comprising an enzyme, an enzyme inhibitor or a receptor ligand or its prodrug; and a method of screening a drug having an excellent administration effect and/or little side effect from among drugs comprising enzymes, enzyme inhibitors or receptor ligands and/or prodrugs thereof. Particularly disclosed is a use of any one of the following compounds (a) to (f): (a) a compound which serves as a substrate for an enzyme contained in a medicine to be evaluated or for an enzyme generated from the prodrug contained in the medicine to be evaluated, or a pharmaceutically acceptable salt thereof, wherein the enzyme is streptokinase, streptodornase, hyaluronidase, urokinase, lysozyme, amylase, saccharated pepsin, diastase or pancreatin; (b) a compound which serves as a substrate for a different enzyme capable of exhibiting an alteration in activity by coupling to the effect of the enzyme contained in the medicine to be evaluated or the effect of an enzyme generated from the prodrug contained in the medicine to be evaluated, or a pharmaceutically acceptable salt thereof, wherein the enzyme is trypsin or carboxypeptidase; (c) a compound which serves as a substrate for an enzyme which is directly inhibited by the enzyme inhibitor contained in the medicine to be evaluated or by an enzyme inhibitor generated from the prodrug contained in the medicine to be evaluated, or a pharmaceutically acceptable salt thereof, wherein the enzyme is alpha-glucosidase, pancreatic protease, HMG-CoA reductase, angiotensin converting enzyme, folate reductase, HIV protease, viral reverse transcriptase, DNA polymerase, neuraminidase or DOPA decarboxylase; (d) a compound which serves as a substrate for an enzyme capable of exhibiting an alteration in activity by coupling to the effect of the enzyme inhibitor for the other enzyme, contained in the medicine to be evaluated or the effect of an enzyme inhibitor generated from the prodrug contained in the medicine to be evaluated, or a pharmaceutically acceptable salt thereof, wherein the enzyme is thymidylate synthase or prostaglandin I synthetase; (e) a compound which serves as a substrate for an enzyme capable of exhibiting an alteration in activity by the binding between a receptor and the receptor ligand contained in the medicine to be evaluated or a receptor ligand generated from the prodrug contained in the medicine to be evaluated, or a pharmaceutically acceptable salt thereof, wherein the enzyme is adenylate cyclase; or (f) a labelled form of any one of the compounds (a) to (e); with the proviso that the compound is not a substrate for PHGPx; in the preparation of a diagnostic reagent which is to be used in a method for evaluating the pharmacological effect of a medicine which contains a pharmaceutical agent comprising an enzyme, an enzyme inhibitor, or a receptor ligand, or a prodrug of the pharmaceutical agent. |
| priorityDate | 2002-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1269.